CRISPR-Cas9

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

CRISPR-Cas9
Sep 25, 2024, 02:31 | Insight
Jennifer Doudna on Advancing CRISPR at Fred Hutchinson Cancer Centre
Fred Hutchinson Cancer Center shared a post on X: “Nobel Laureate Jennifer A. Doudna kicked…
Aug 7, 2024, 12:11 | Insight
Delineating the Role of Mitochondrial Dysregulation in Richter’s Transformation
Chronic lymphocytic leukemia (CLL) is a mature B cell disease identified by the aberrant expression…
Jul 4, 2024, 15:05 | Insight
Susanna Greer: Next target - neuroblastoma
Susanna Greer, Chief Scientific Officer at The V Foundation for Cancer Research, shared on LinkedIn: …
Jul 2, 2024, 05:00 | Insight
AlphaFold’s recent advancements and its potential impact on predictive medicine
AI in Precision Oncology  shared a post on X: "AIPO is excited to publish a…
Jul 2, 2024, 04:16 | Insight
Olivier Calvayrac: TT-derived drug-tolerant (DT) lung cancer cells are vulnerable to FTIs
Olivier Calvayrac, Research Scientist at the Toulouse Cancer Research Center, shared a post on X…
May 2, 2024, 13:23 | Insight
Marco Donia: Welcoming the Era of Gene Editing in Medicine
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared on LinkedIn: "Autologous…
May 1, 2024, 00:59 | Insight
Angela Mastronuzzi: Yet another impactful and giant step in clinical research
Angela Mastronuzzi shared on LinkedIn: "Also out with The NEW ENGLAND JOURNAL of MEDICINE of the NEJM Group:…
Jan 15, 2024, 01:31 | Insight
Eytan Ruppin: The very first systematic review and analysis on synthetic lethality in oncology
Quoting Eytan Ruppin, Chief at the Cancer Data Science Lab of the National Institute of Health…
All: 8 Posts: 1 - 100
Special Coverage